Eli Lilly v. Medtronic: The Section 271(e)(1) Safe Harbor Reaches Devices

Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990), decided June 18, 1990, is the case that defined the reach of the Hatch-Waxman research exemption across the entire universe of FDA-regulated products. Writing for the Court, Justice Scalia held that the safe harbor of 35 U.S.C. § 271(e)(1) exempts activity undertaken to develop and submit information for federal marketing approval of medical devices, not merely drugs. The opinion is a model of structural statutory interpretation and remains the foundational authority on who may use a patented invention, and for what, during the regulatory-approval process.

At a glance

• Case: Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990), No. 89-243
• Decided: June 18, 1990; opinion by Justice Scalia, with a dissent; affirming the Court of Appeals for the Federal Circuit
• Holding: The § 271(e)(1) safe harbor exempts otherwise-infringing activity reasonably related to obtaining FDA marketing approval under the Food, Drug, and Cosmetic Act, and that exemption reaches medical devices, not only drugs
• Status: Final; governing authority, later supplemented on scope by Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005)

The problem the 1984 Act was written to solve

The Drug Price Competition and Patent Term Restoration Act of 1984, universally known as Hatch-Waxman, was Congress’s response to two distortions of the nominal patent term produced by the requirement of premarket regulatory approval. At the front end, a patentee lost effective term while the product sat in FDA review and could not be sold. At the back end, a competitor could not begin the testing needed to seek approval of a generic or competing product until the patent expired, because that testing would itself infringe. The result was a patent that ran short at the start of its life and long at the end.

Congress addressed both distortions with paired provisions. Section 156 of the Patent Act authorized patent-term extension to restore time lost to regulatory review. Section 271(e)(1) created a safe harbor: it is not an act of infringement to make, use, or sell a patented invention solely for uses reasonably related to the development and submission of information under a federal law that regulates the manufacture, use, or sale of drugs. Together the two provisions were meant to let competitors do their regulatory homework during the patent term while giving patentees compensating term restoration.

The dispute: a defibrillator, not a pill

Eli Lilly owned patents relevant to implantable cardiac defibrillators. Medtronic tested and worked toward marketing a competing device, gathering the data needed for premarket approval under the Food, Drug, and Cosmetic Act. Sued for infringement, Medtronic invoked § 271(e)(1). Lilly answered that the safe harbor is a drug provision: the phrase “a Federal law which regulates the manufacture, use, or sale of drugs,” Lilly argued, refers only to those provisions of federal law that regulate drugs, and a defibrillator is a device, not a drug. Medtronic countered that the phrase refers to any federal statute at least some of whose provisions regulate drugs, which the Food, Drug, and Cosmetic Act plainly is, and that statute regulates devices as well.

The Federal Circuit sided with Medtronic. The Supreme Court granted certiorari to resolve the reach of the exemption.

The reasoning: text ambiguous, structure decisive

Justice Scalia began where a textualist begins, with the words, and candidly conceded they did not resolve the case. The operative phrase was ambiguous. It was somewhat more natural, he acknowledged, to read “a Federal law which regulates the manufacture, use, or sale of drugs” as Medtronic did, to mean an entire Act (such as the FDCA) some of whose provisions regulate drugs, rather than as Lilly did, to mean only the individual drug-specific provisions. But the text standing alone was imprecise and not plainly comprehensible on either reading.

The Court therefore turned to structure, and the structure was decisive. Section 271(e)(1) does not stand by itself. It is one half of a symmetrical bargain with the patent-term-extension provisions of § 156. Those extension provisions unambiguously covered medical devices along with drugs and other regulated products. Congress had built a scheme in which the burden imposed on patentees by the safe harbor was offset by the benefit of term restoration. Reading the safe harbor to cover only drugs while term extension covered devices would break that symmetry, granting device patentees the benefit of extension without the corresponding infringement exemption that justified it, and denying device competitors the exemption that their drug counterparts enjoyed. To keep the two halves of the 1984 Act coherent, the safe harbor had to reach the same products as the extension provisions. Medtronic’s device-testing activity therefore fell within § 271(e)(1).

What the decision changed

Eli Lilly converted a drug-price statute into a general framework for regulated-product patent litigation. After the decision, the safe harbor was no longer a pharmaceutical carve-out. Any competitor working to satisfy FDA premarket requirements for a device, and by extension other FDCA-regulated categories, could invoke § 271(e)(1) for activity reasonably related to that submission. The case is the necessary predicate to every later dispute about the exemption, including the scope question the Court reached fifteen years later in Merck KGaA v. Integra Lifesciences I, Ltd., which addressed how far upstream preclinical research can reach while remaining reasonably related to an eventual FDA submission.

Open questions

Eli Lilly fixed the products the safe harbor covers but deliberately left its temporal and substantive boundaries for another day. How attenuated can research be, how early and how exploratory, before it is no longer reasonably related to the development and submission of information to the FDA? The Court did not say, and Merck v. Integra answered only part of it, holding the exemption broad enough to cover preclinical work with a reasonable basis to believe it will generate the kind of information a regulatory submission requires. The device context raises its own unresolved wrinkles because device approval pathways differ from the drug abbreviated-application model, and the fit between § 271(e)(1) and evolving FDA device frameworks continues to generate litigation. The interaction of the safe harbor with research tools, whose value lies precisely in their use during development, also remains contested.

Implications for inventors and businesses

• Treat the safe harbor as universe-wide. If your competitor’s use of a patented invention is genuinely aimed at an FDA submission, whether for a drug, a device, or another regulated product, § 271(e)(1) is in play. Do not assume a device patent is immune from the exemption.
• Anchor infringement strategy in purpose, not product. After Eli Lilly, the decisive question is whether the accused activity is reasonably related to regulatory submission. Build the factual record around intent and use, because that is where the exemption is won or lost.
• Coordinate term extension and freedom-to-operate. The 1984 Act pairs the safe harbor with § 156 term restoration. Portfolio planning should treat the two as a package, weighing the exemption competitors will enjoy against the extension the patentee can recover.
• Watch the scope frontier. Eli Lilly is the door; Merck v. Integra is the room. Frame preclinical and exploratory research programs with the reasonably-related standard in mind so that protected activity stays protected.

Frequently asked questions

What does the Section 271(e)(1) safe harbor actually protect? It shields from infringement the making, using, or selling of a patented invention when reasonably related to developing and submitting information under a federal law that regulates the manufacture, use, or sale of drugs. Eli Lilly held that this reaches medical devices approved under the Food, Drug, and Cosmetic Act, not only pharmaceuticals.

Why did the Court read an ambiguous statute in Medtronic’s favor? Justice Scalia found the phrase “a Federal law which regulates the manufacture, use, or sale of drugs” genuinely ambiguous, then resolved it by the structure of the 1984 Act. Because the patent-term-extension provisions plainly covered devices, symmetry required the safe harbor to cover them too.

Did Eli Lilly settle how broad “reasonably related” is? No. The decision fixed which products the safe harbor covers but not how far preclinical or exploratory research can stray while remaining reasonably related to FDA submission. The Supreme Court answered that scope question later in Merck KGaA v. Integra Lifesciences I.

Authorities and sources

• Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990), No. 89-243 (June 18, 1990), Cornell LII and the bound-volume PDF at the Library of Congress.
• 35 U.S.C. § 271(e)(1) (safe harbor) and 35 U.S.C. § 156 (patent-term extension).
• Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman).
• Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005) (scope of “reasonably related”).
• Wikipedia, “Eli Lilly & Co. v. Medtronic, Inc.” and Quimbee case brief.